A potential vaccine developed by University of Guelph researchers to combat one of the main causes of bacterial diarrheal illness worldwide is set to be tested on people early this year.
Human clinical trials of a novel sugar-based vaccine will take place in 2022 at the Cincinnati Children’s Hospital Medical Center. The trials will be funded by the United States National Institutes of Health.
Dr. Mario Monteiro, a professor in the College of Engineering and Physical Sciences, hopes recent refinements to the vaccine in his lab following earlier phase one trials will improve its effectiveness against the Campylobacter jejuni bacterium.
FoodWorld 